Securities Investigation On Behalf of Fortress Biotech Investors – FBIO Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fortress Biotech, Inc. (“Fortress Biotech” or the “Company”) (NASDAQ: FBIO) to determine whether the Company engaged in securities fraud or other unlawful business practices.
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE SECURITIES OF FORTRESS BIOTECH BETWEEN DECEMBER 11, 2019 AND OCTOBER 9, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
On November 27, 2020, a class action lawsuit was filed against Fortress Biotech in United States District Court, Eastern District of New York.
According to the class action complaint, throughout the Class Period, the Fortress Biotech Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, according to the class action complaint, the Fortress Biotech Defendants made false and/or misleading statements and/or failed to disclose that IV Tramadol was not safe for the intended patient population, and that it was foreseeable to them that the FDA would not approve the New Drug Application for IV Tramadol.